Sensorion (ALSEN) H2 2025 earnings summary

Executive summary

• Advanced gene therapy pipeline with SENS-501 and GJB2-GT, targeting congenital hearing loss.

• Achieved key clinical milestones, including positive safety and early efficacy signals for SENS-501.

• Strengthened financial position with €60m financing, including €20m from Sanofi, extending cash runway to end of H1 2027.

• Leadership transition with Amit Munshi appointed as Chairman and Interim CEO following the departure of the previous CEO.

Financial highlights

• Cash and cash equivalents at €47.5m as of December 31, 2025, down from €77.0m at year-end 2024.

• R&D expenses increased 12% year-over-year to €28.8m in 2025.

• G&A expenses decreased to €7.7m from €9.4m in 2024.

• Net loss widened to -€29.4m in 2025 from -€26.0m in 2024.

Outlook and guidance

• Sufficient net working capital to meet cash requirements until end of June 2027.

• SENS-501 six-month efficacy data expected in Q1 2026; GJB2-GT CTA submission on track for H1 2026.